Hertility Health, a new women’s health start-up revolutionising the world of hormone and reproductive health, has closed a GBP4.2 million seed funding round led by LocalGlobe, Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, and CEO of Nested and the unicorn company GoCardless, Matt Robinson.
The funds will help Hertility Health expand its current product offering of fertility and hormone testing, menopause, miscarriage, postnatal care, polycyctic ovarian syndrome (PCOS) and endometriosis testing, as well as aid the expansion of its current clinical trials which aim to reduce the diagnosis time for some of the most common reproductive conditions. This cash injection will also work towards establishing Hertility Health as the leading scientific and clinical educational health hub for women in a sector that’s set to be worth USD50 billion by 2025.
For far too long, women have been reactive when it comes to their fertility, only seeking answers once they think something is wrong. Hertility Health has already helped over 2,000 women understand their reproductive health and infertility risks, working with leading world experts to provide personalised care pathways that help with all aspects of women’s health, including symptom management, egg freezing and IVF. In recognising the sensitive nature of these results, Hertility Health also offers fertility counselling to those in need.
“We live in a society that expects us to tolerate pain and mask our symptoms. Some women spend over ten years on their contraception, never fully knowing if there might be something wrong,” says Hertility Health CEO and Founder, Dr Helen O’Neill.
On average, one in five Hertility Health users have been found to have a previously undiagnosed reproductive condition which has been revealed as a result of testing with Hertility Health.
